Zipsor

Type: Product
Name: Zipsor
First reported Aug 18 2014 - Updated Aug 18 2014 - 1 reports

MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally Ripe To Go Up In the Next Five Weeks

BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mannkind Corp (NASDAQ:MNKD), Depomed Inc (NASDAQ:DEPO), Dj Wilshire Reit Etf (NYSE:RWR), NetEase.com Inc (NASDAQ:NTES), Tata Motors Ltd (NYSE:TTM), VeriFone Systems Inc (NYSE:PAY) and ... [Published Individual.com - Aug 18 2014]
First reported Aug 08 2014 - Updated Aug 08 2014 - 1 reports

Depomed Shares Offer 50% Upside Over The Next Six Months

Summary Depomed Q2 financial results exceed Street expectations based on strong product sales and royalties. The company raised guidance on their second quarter call. Business fundamentals looks strong. We expect the company to win its ANDA patent litigation ... [Published Seeking Alpha - Aug 08 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 2 reports

DepoMed's (DEPO) CEO James Schoeneck on Q2 2014 Results - Earnings Call Transcript

OperatorGood afternoon, and welcome to the Depomed Reports Second Quarter Fiscal Year 2014 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to August Moretti, ... [Published Seeking Alpha - Aug 07 2014]
Entities: Gralise, Depomed Inc, Zipsor
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Depomed Announces Appointment of R. Scott Shively as Chief Commercial Officer

NEWARK, Calif., Aug. 4, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of R. Scott Shively, as Chief Commercial Officer and Senior Vice President. Mr. Shively has extensive commercial leadership experience in sales and ... [Published TickerTech.com - Aug 04 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 2 reports

Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014

NEWARK, Calif.Participants can access the call by dialing 877-317-6789 (United StatesAbout DepomedDepomed is a specialty pharmaceutical company that commercializes products for pain and neurology related disorders. Gralise® (gabapentin) is a once-daily ... [Published Bio-Medicine - Jul 25 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 2 reports

Depomed Announces District Court Order in ANDA Litigation

NEWARK, Calif.On May 20, 2014, a bench trial was completed before Judge Pisano in the patent litigation between Depomed and defendants Actavis Elizabeth LLC and Actavis Inc. related to an Abbreviated New Drug Application filed by Actavis seeking to market ... [Published Bio-Medicine - Jul 17 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Depomed Announces Appointment of Srinivas G. Rao, MD, PhD, as Chief Medical Officer

SOURCE Depomed, Inc.NEWARK, Calif. , July 16, 2014 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced the appointment of Srinivas G. Rao , MD, PhD, as Chief Medical Officer and Senior Vice President.   Dr. Rao has extensive experience and background ... [Published KSFY - Jul 16 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Tulsa, OK-Pharmaceutical Sales Representative

OverviewinVentiv Health offers best-in-class Clinical, Consulting and Commercial services to global companies seeking to accelerate performance. With 13,000 employees in 40 countries, we rapidly transform promising ideas into commercial reality. inVentiv ... [Published PharmaDiversity - Jul 16 2014]
First reported Jun 22 2014 - Updated Jun 22 2014 - 1 reports

ZIPSOR (Diclofenac Potassium) Capsule, Liquid Filled [Depomed, Inc.]

Entities: Zipsor, Depomed Inc

Quotes

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."
...four of our products showed prescription growth in Q2 compared to Q1 2014," said Jim Schoeneck, President and Chief Executive Officer of Depomed. "We believe the growth of our product revenues in Q2 and the integration of new products into our commercial organization demonstrate our ability to build a growth-oriented specialty pharmaceutical company focused on pain and central nervous system disorders. We are also thrilled to add Srini and Scott to our leadership team, increasing our depth and expertise in the pain and CNS markets. For the remainder of 2014, we are focused on growing product revenues, acquiring additional assets that will enhance our product portfolio and managing expenses to continue to operate at positive cash flow."
"We are extremely pleased to have Scott join us as Chief Commercial Officer," said Jim Schoeneck, President and Chief Executive Officer. "He has deep experience commercializing products for pain and has spent much of his career helping companies significantly grow their business. This is an exciting time at Depomed. With our strong base of four marketed products and our intent to acquire additional assets, we believe that Scott's background in managing large, multi-product sales forces and marketing teams will help us accomplish our goals. His experience in growing organizations is a great fit for Depomed as we build a leading specialty pharmaceutical company focused on pain and central nervous system disorders."
"We are delighted to have Srini join us as Chief Medical Officer", said Jim Schoeneck , President and Chief Executive Officer.  "His deep expertise in the areas of pain and neurology and his experience in in-licensing and directing the clinical development and approval of medicines to treat important CNS conditions make him a great fit for Depomed as we seek to expand our franchise in pain and central nervous system diseases."

More Content

All (14) | News (13) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
MNKD, DEPO, RWR, NTES, TTM, PAY Are Seasonally ... [Published Individual.com - Aug 18 2014]
Depomed Shares Offer 50% Upside Over The Next S... [Published Seeking Alpha - Aug 08 2014]
DepoMed's (DEPO) CEO James Schoeneck on Q2 2014... [Published Seeking Alpha - Aug 07 2014]
Depomed Reports Second Quarter 2014 Financial R... [Published TickerTech.com - Aug 06 2014]
Seattle, WA-Oncology Sales Representative [Published PharmaDiversity - Aug 05 2014]
Depomed Announces Appointment of R. Scott Shive... [Published TickerTech.com - Aug 04 2014]
Depomed To Report Second Quarter Fiscal Year 20... [Published Bio-Medicine - Jul 25 2014]
Depomed To Report Second Quarter Fiscal Year 20... [Published Reuters - Jul 25 2014]
Buffalo, NY- Pharmaceutical Sales Representative [Published PharmaDiversity - Jul 23 2014]
Depomed Announces District Court Order in ANDA ... [Published Bio-Medicine - Jul 17 2014]
Depomed Announces District Court Order in ANDA ... [Published KSFY - Jul 17 2014]
Depomed Announces Appointment of Srinivas G. Ra... [Published KSFY - Jul 16 2014]
Tulsa, OK-Pharmaceutical Sales Representative [Published PharmaDiversity - Jul 16 2014]
ZIPSOR (Diclofenac Potassium) Capsule, Liquid F... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ZIPSOR (Diclofenac Potassium) Capsule, Liquid F... [Published DailyMed Drug Label Updates for the last seven ... - Jun 22 2014]
Updated Date: Jun 18, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.